Incidence of T790M in patients with NSCLC progressed to gefitinib, erlotinib, and afatinib: a study on circulating cell-free DNA
Background Insights into the mechanism of resistance to epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) could provide important information for further …
(EGFR) tyrosine kinase inhibitors (TKIs) could provide important information for further …
The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
Background Lung cancer patients with an activating mutation in the EGFR (epidermal
growth factor receptor) can develop resistance to erlotinib treatment, which is often mediated …
growth factor receptor) can develop resistance to erlotinib treatment, which is often mediated …
Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer
Y Kuang, A Rogers, BY Yeap, L Wang… - Clinical Cancer …, 2009 - AACR
Purpose: Tumors from 50% of epidermal growth factor receptor (EGFR) mutant non–small
cell lung cancer patients that develop resistance to gefitinib or erlotinib will contain a …
cell lung cancer patients that develop resistance to gefitinib or erlotinib will contain a …
[HTML][HTML] Selective gene amplification to detect the T790M mutation in plasma from patients with advanced non-small cell lung cancer (NSCLC) who have developed …
S Nishikawa, H Kimura, H Koba, T Yoneda… - Journal of Thoracic …, 2018 - ncbi.nlm.nih.gov
Background The epidermal growth factor receptor (EGFR) T790M mutation is associated
with resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer …
with resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer …
Five Technologies for Detecting the EGFR T790M Mutation in the Circulating Cell-Free DNA of Patients With Non-small Cell Lung Cancer: A Comparison
YL Chen, CC Lin, SC Yang, WL Chen, JR Chen… - Frontiers in …, 2019 - frontiersin.org
Third-generation tyrosine kinase inhibitors (TKIs) were developed to overcome T790M-
mediated resistance to earlier generations of epidermal growth factor receptor (EGFR) …
mediated resistance to earlier generations of epidermal growth factor receptor (EGFR) …
[HTML][HTML] Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer …
K Tanaka, K Nosaki, K Otsubo, K Azuma, S Sakata… - Oncotarget, 2017 - ncbi.nlm.nih.gov
The T790M secondary mutation of the epidermal growth factor receptor (EGFR) gene
accounts for 50% to 60% of cases of resistance to the first-generation EGFR tyrosine kinase …
accounts for 50% to 60% of cases of resistance to the first-generation EGFR tyrosine kinase …
Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC
Z Wang, R Chen, S Wang, J Zhong, M Wu, J Zhao… - PloS one, 2014 - journals.plos.org
Background Among advanced non-small cell lung cancer (NSCLC) patients with an
acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR …
acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR …
Association of EGFR exon 19 deletion and EGFR-TKI treatment duration with frequency of T790M mutation in EGFR-mutant lung cancer patients
N Matsuo, K Azuma, K Sakai, S Hattori, A Kawahara… - Scientific Reports, 2016 - nature.com
The most common event responsible for resistance to first-and second-generation (1st and
2nd) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is acquisition of …
2nd) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is acquisition of …
Association between EGFR T790M status and progression patterns during initial EGFR-TKI treatment in patients harboring EGFR mutation
Y Oya, T Yoshida, H Kuroda, J Shimizu, Y Horio… - Clinical lung cancer, 2017 - Elsevier
Background Emergence of the T790M point mutation in exon 20 of the epidermal growth
factor receptor (EGFR) is the most common mechanism of resistance to EGFR tyrosine …
factor receptor (EGFR) is the most common mechanism of resistance to EGFR tyrosine …
[HTML][HTML] Detection of plasma T790M mutation after the first generation EGFR-TKI resistance of non-small cell lung cancer in the real world
H Li, J Wang, G Zhang, Y Li, L Lin, H Yang… - Journal of thoracic …, 2020 - ncbi.nlm.nih.gov
Background The epidermal growth factor receptor (EGFR) gene has been identified as the
driving gene of non-small cell lung cancer (NSCLC), and EGFR-tyrosine kinase inhibitor …
driving gene of non-small cell lung cancer (NSCLC), and EGFR-tyrosine kinase inhibitor …
相关搜索
- gefitinib erlotinib and afatinib
- incidence of t790m patients with nsclc
- t790m mutation egfr tki
- t790m mutation lung cancer
- nsclc patients egfr mutation
- egfr mutations afatinib treatment
- t790m mutation treatment duration
- t790m mutation clinical likelihood
- digital pcr egfr t790m
- dynamic monitoring egfr t790m
- progression patterns egfr mutation
- treatment duration egfr tki
- real world egfr tki
- clinical likelihood lung cancer
- afatinib treatment naïve patients
- t790m mutation egfr exon